Improving treatment intensification to reduce cardiovascular disease risk: a cluster randomized trial

Table 2 Treatment Intensification Rates, Baseline Risk Factor Levels, Declines and Adjusted Differences During Follow-up - Study vs. Control Centers, Eligible Patients, by Priority Level

	Study (n = 4 sites)				Control (n = 4 sites)
Priority	Number Eligible Patients	Intensified within 3 months	Baseline Mean Risk Factor Level ^†	Unadjusted Risk Factor Decline ^‡	Number Eligible Patients	Intensified within 3 months	Baseline Mean Risk Factor Level ^†	Unadjusted Risk Factor Decline ^‡	Adjusted Study-Control Risk Factor Differences (95% CI) ^¶
1: SBP ≥ 140	3,080	34.1^€	153.2	13.6	2,905	30.6^€	153.0	13.4	0.73
1: SBP ≥ 140	3,080	34.1^€	153.2	13.6	2,905	30.6^€	153.0	13.4	(-1.40, 2.83)
2: LDL-c ≥ 130	2,431	28.0^€	153.1	24.9	1,789	22.7^€	153.9	23.8	-2.63
2: LDL-c ≥ 130	2,431	28.0^€	153.1	24.9	1,789	22.7^€	153.9	23.8	(-6.73, 1.48)
3: A1c ≥ 9%	1,318	29.5	10.2	1.0	1,059	28.8	10.2	1.2	-0.02
3: A1c ≥ 9%	1,318	29.5	10.2	1.0	1,059	28.8	10.2	1.2	(-0.36, 0.32)
4:SBP 130-139^£	3,878	22.9	138.5	6.0	3,583	22.0	138.5	5.0	-0.00
4:SBP 130-139^£	3,878	22.9	138.5	6.0	3,583	22.0	138.5	5.0	(-1.25, 1.26)
5: LDL-c 100-129	4,876	20.5	111.4	10.1	3,526	19.1	111.3	8.9	-0.83
5: LDL-c 100-129	4,876	20.5	111.4	10.1	3,526	19.1	111.3	8.9	(-4.10, 2.44)
6. A1c 7-8.9%	3,750	26.3	7.5	0	3,007	26.9	7.5	0	0.03
									(-0.10, 0.16)

^† Based on the last value recorded before follow-up begins; i.e., the value that qualified patient for treatment intensification.
^‡ Based on the first value recorded after 3 months follow-up; if no values recorded between 3 and 12 months follow-up, the latest value recorded during first 3 months follow-up was used. No values were available during follow-up for 3%, 10%, and 14% of blood pressure, A1c, and LDL-c tests, respectively.
^¶ From repeated measures models using all available values during follow-up,with adjustment for age, gender, race-ethnicity, baseline risk factor value, number of medications for the risk factor at baseline, and days of follow-up at time of each measurement. Negative value indicates that the adjusted difference favored the study group group during follow-up.
^€ p < 0.001 for study vs. control comparison.
^£ Only patients with diabetes mellitus and/or chronic kidney disease were eligible for the target of SBP <130 mmHg.

ISSN: 1472-6963